On June 8, 2024, the Board of Vor Biopharma Inc. designated Robert Ang, M.B.B.S., M.B.A., the Company?s President and Chief Executive Officer and a director of the Company, as the Company?s interim principal financial officer and Amy Quinlan, the Company?s Vice President of Finance, as the Company?s interim principal accounting officer, effective June 21, 2024. Information regarding Dr. Ang?s background and business experience is set forth under the caption ?Class III Nominees for Election for a Three-Year Term Expiring at the 2027 Annual Meeting? in the Company?s definitive proxy statement filed with the Securities and Exchange Commission on April 9, 2024 and is incorporated herein by reference.

There are no arrangements or understandings between Dr. Ang and any other persons pursuant to which he was selected as an officer or director of the Company. There are also no family relationships between Dr. Ang and any director or executive officer of the Company, and Dr. Ang has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Ms. Quinlan, age 49, has served as the Company?s Vice President of Finance since September 2020. Prior to that, Ms. Quinlan served as Vice President, Controller at TetraPhase Pharmaceuticals Inc. from 2008 to August 2020.

Ms. Quinlan received her Bachelor of Science degree from Bryant University. There are no arrangements or understandings between Ms. Quinlan and any other persons pursuant to which she was selected as an officer of the Company. There are also no family relationships between Ms. Quinlan and any director or executive officer of the Company, and Ms. Quinlan has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.